Clinical Trials

Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have…

Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device,…

Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…